REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development ...

Researchers discovered that gut microbiota-derived hexa-acylated LPS enhances the effectiveness of anti-PD-1 cancer ...

Immunotherapy revolutionises cancer treatment by harnessing the immune system, offering targeted therapy with fewer side ...

Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Despite hosting more oncology start-ups, Europe is lagging in the development of cancer technologies, losing the competitive ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...

A groundbreaking immunotherapy is showing unprecedented success against one of the deadliest childhood brain cancers — ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

A2A receptor antagonists have been extensively studied as agents in cancer immunotherapy. By blocking A2A receptors, these antagonists can restore T-cell proliferation and boost cytokine production.